Novel Apoptosis-Inducing Constructs for User Against Carcinomas

Inventor
W.T. Godbey, Ph.D.

Tulane University is actively seeking companies interested in commercializing novel constructs which effectively induce apoptosis in cancer cells. The novel approach employs two caspases to achieve a synergistic effect, resulting in a more substantial level of cell death in the targeted cancer cells.

Applications
- Provides effective initiation of the apoptosis cascade in cancer cells that overexpress cyclooxygenase-2 (Cox-2)
- Includes use in cancers of the colon, prostate, bladder, stomach, and esophagus

Advantages
- Based on proven method of apoptosis to treat cancer
- Degradation products are packaged and undergo phagocytosis
- Low toxicity profile

Development Status
This technology has been tested extensively in vitro and in vivo in a mouse model, with results strongly supporting the anti-cancer applications. Human trials are in development. Laboratory work is ongoing to produce more effective species of these constructs.

Available For
- Exclusive Licensing in a Field
- Non-exclusive Licensing
- Scientific Collaboration

For more information, please contact:
Justin Levy
Licensing Associate
504-988-6962
jlevy5@tulane.edu
Novel Apoptosis-Inducing Constructs for User Against Carcinomas

Related Publications


